These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8144911)

  • 1. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast killer toxin-like anti-idiotypic antibodies.
    Polonelli L; De Bernardis F; Conti S; Boccanera M; Gerloni M; Morace G; Magliani W; Chezzi C; Cassone A
    J Immunol; 1994 Mar; 152(6):3175-82. PubMed ID: 8144911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human natural yeast killer toxin-like candidacidal antibodies.
    Polonelli L; De Bernadis F; Conti S; Boccanera M; Magliani W; Gerloni M; Cantelli C; Cassone A
    J Immunol; 1996 Mar; 156(5):1880-5. PubMed ID: 8596040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity.
    Magliani W; Conti S; de Bernardis F; Gerloni M; Bertolotti D; Mozzoni P; Cassone A; Polonelli L
    Nat Biotechnol; 1997 Feb; 15(2):155-8. PubMed ID: 9035141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes.
    Magliani W; Conti S; Salati A; Vaccari S; Ravanetti L; Maffei DL; Polonelli L
    FEMS Yeast Res; 2004 Oct; 5(1):11-8. PubMed ID: 15381118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yeast killer toxin-like anti-idiotypic antibodies.
    Polonelli L; Morace G
    J Clin Microbiol; 1988 Mar; 26(3):602-4. PubMed ID: 2451680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity.
    Polonelli L; Lorenzini R; De Bernardis F; Gerloni M; Conti S; Morace G; Magliani W; Chezzi C
    Scand J Immunol; 1993 Jan; 37(1):105-10. PubMed ID: 8418467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade.
    Polonelli L; Beninati C; Teti G; Felici F; Ciociola T; Giovati L; Sperindè M; Lo Passo C; Pernice I; Domina M; Arigò M; Papasergi S; Mancuso G; Conti S; Magliani W
    PLoS One; 2014; 9(8):e105727. PubMed ID: 25162681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies.
    Polonelli L; Séguy N; Conti S; Gerloni M; Bertolotti D; Cantelli C; Magliani W; Cailliez JC
    Clin Diagn Lab Immunol; 1997 Mar; 4(2):142-6. PubMed ID: 9067647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killer anti-idiotypes in the control of fungal infections.
    Magliani W; Conti S; Arseni S; Frazzi R; Salati A; Polonelli L
    Curr Opin Investig Drugs; 2001 Apr; 2(4):477-9. PubMed ID: 11566002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medical importance of yeast killer toxin].
    Cerikcioğlu N
    Mikrobiyol Bul; 2003; 37(2-3):215-21. PubMed ID: 14593905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats.
    De Bernardis F; Boccanera M; Adriani D; Spreghini E; Santoni G; Cassone A
    Infect Immun; 1997 Aug; 65(8):3399-405. PubMed ID: 9234804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of anti-toxin antibodies by immunization with Pichia killer toxin-like antiidiotypic monoclonal antibodies.
    Snyder C; Seguy N; Lafitte S; Guyard C; Polonelli L; Cailliez JC; Grzych JM
    J Eukaryot Microbiol; 1999; 46(5):138S. PubMed ID: 10519290
    [No Abstract]   [Full Text] [Related]  

  • 13. Human, monoclonal and recombinant candidacidal, pneumocysticidal and mycobactericidal antibodies.
    Polonelli L
    Indian J Chest Dis Allied Sci; 2000; 42(4):259-63. PubMed ID: 15597672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine.
    Sandini S; La Valle R; Deaglio S; Malavasi F; Cassone A; De Bernardis F
    FEMS Immunol Med Microbiol; 2011 Jul; 62(2):215-24. PubMed ID: 21535228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes.
    De Bernardis F; Santoni G; Boccanera M; Lucciarini R; Arancia S; Sandini S; Amantini C; Cassone A
    FEMS Yeast Res; 2010 Jun; 10(4):432-40. PubMed ID: 20402794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interfaces of the yeast killer phenomenon.
    Polonelli L; Conti S; Gerloni M; Magliani W; Chezzi C; Morace G
    Crit Rev Microbiol; 1991; 18(1):47-87. PubMed ID: 1854433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiotypy of human anti-Candida albicans antibodies: recurrence, presence of a cross-reactive autoanti-idiotypic-like activity, and role in the induction of specific in vitro antibody response.
    de Saint Basile G; Durandy A; Somme G; Griscelli C
    J Immunol; 1987 Jan; 138(2):417-22. PubMed ID: 3540120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique.
    Pietrella D; Rachini A; Torosantucci A; Chiani P; Brown AJ; Bistoni F; Costantino P; Mosci P; d'Enfert C; Rappuoli R; Cassone A; Vecchiarelli A
    Vaccine; 2010 Feb; 28(7):1717-25. PubMed ID: 20038431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.
    Han Y; Morrison RP; Cutler JE
    Infect Immun; 1998 Dec; 66(12):5771-6. PubMed ID: 9826353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals.
    Manfredi M; McCullough MJ; Conti S; Polonelli L; Vescovi P; Al-Karaawi ZM; Porter SR
    Oral Microbiol Immunol; 2005 Aug; 20(4):226-32. PubMed ID: 15943767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.